[Clinical application of 6059-S in the field of obstetrics and gynecology. Effects on gynecological infection and infection of trimester of pregnancy (author's transl)].
6059-S, a new oxacephem antibiotic was applied in the clinical use of gynecological and obstetrical infection. 1. In obstetrical field, attention should be paid on choice of antibiotics in the case of maternal infection. Especially in the trimester of pregnancy, such drugs as ampicillin (ABPC) has been reported apparent unfavourable effects by decreasing the estriol (E3) level. 2. The comparative study between 6059-S, SBPC and ABPC was performed by various hormone level, including E3 (blood and urine), blood progesterone, alpha-fetoprotein, human chorionic gonadotropin (HCG), cortisol and human placental lactogen (HPL). 9 cases of intrauterine fetal growth retardation (IUGR) (ranging from 28 approximately 36 weeks of pregnancy) was selected, including toxemia of pregnancy or complicated pregnancy of myoma of uterus and diabetes mellitus. The determination of hormone level, one drug (2g) out of three test drug was chosen at random and administered by intravenous infusion on 3 approximately 4 days after admission. After 5 days of interval, another test dose was given, and the evaluation between the drug effects was performed on the hormonal level. 3. Following the single administration of ABPC (2 g) by intravenous infusion, the decrease of urinary E3 reached 26% on the 2 days after injection. As for SBPC the decrease was 21%, while in cases 6059-S, no apparent change was determined. Statistical difference between 6059-S and ABPC 5% by chi 2 determination was found. On the other hormonal level, there was relatively great individual difference, and the apparent day by day change was undeterminable. 4. Clinical estimation of 6095-S on the gynecological infection was also performed on the 7 cases of patients. The overall efficacy rate was 85.7%. No adverse reaction was observed except one case elevation of S-GPT.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D002511:Cephalosporins / Q000009:adverse effects*; D002513:Cephamycins / Q000009:adverse effects*; D004341:Drug Evaluation; D004964:Estriol / Q000097:blood*; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood*; D005831:Genital Diseases, Female / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D009070:Moxalactam; D010925:Placental Function Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011263:Pregnancy Trimester, Third; D011374:Progesterone / Q000097:blood
D002511:Cephalosporins; D002513:Cephamycins; D011374:Progesterone; D004964:Estriol; D009070:Moxalactam